AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04476992
Drug: Nitric Oxide-Continuous and Sessions
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm.
Trial: NCT01533545
Drug: Mepivacaine with epinephrine
RxNorm normalized name: epinephrine / mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
Trial: NCT01451645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily placebo dosing for 16 weeks
Trial: NCT00854646
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
Trial: NCT00003490
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00906386
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 1 mg twice daily, 12 weeks
Trial: NCT00217165
Drug: taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: taurine 2mg BID po
Trial: NCT01982812
Drug: Standard AED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparitor, Standard AED
Trial: NCT01966549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
Trial: NCT01342094
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01578161
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,Normal saline 10ml ivs. for 10min.
Trial: NCT00949325
Drug: temsirolimus plus liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
Trial: NCT02515318
Drug: Medical standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Trial: NCT02891226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01737892
Drug: Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
Trial: NCT01737892
Drug: Arm C-Epinephrine Inhalation Aerosol CFC
RxNorm normalized name: epinephrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
Trial: NCT00896532
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg administered intravenously
Trial: NCT02363075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
Trial: NCT01634152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 actuations once daily in the evening
Trial: NCT03093714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for FDL169
Trial: NCT01349114
Drug: Placebo/sugar pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill/placebo
Trial: NCT01152437
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
Trial: NCT01480778
Drug: LNG+EE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Trial: NCT00237042
Drug: 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
Trial: NCT00278109
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT01468480
Drug: Pro Root MTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of MTA in second group and 24 hour interval before restoration
Trial: NCT01468480
Drug: Pro Root MTA- single visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of MTA in third group and 15 minute interval before restoration
Trial: NCT01468480
Drug: MultiCal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of Multical in forth group as a pulp dressing agent
Trial: NCT01468480
Drug: Dycal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of Dycal in first group as a pulp dressing agent
Trial: NCT00278109
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin
Trial: NCT00720057
Drug: Naproxen Sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
Trial: NCT00720057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
Trial: NCT02208856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01314833
Drug: Docetaxel Cyclophosphamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6
Trial: NCT01314833
Drug: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3
Trial: NCT01314833
Drug: Epirubicin Cyclophosphamide Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4
Trial: NCT02409459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution
Trial: NCT01317745
Drug: MF59 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant/diluent manufactured by Novartis
Trial: NCT02232542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00613015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00530881
Drug: PHX1149
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03659578
Drug: thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
Trial: NCT01145950
Drug: LBEC0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25mg, single dose
Trial: NCT02332928
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Trial: NCT02332928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Trial: NCT01265485
Drug: coated suppository
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalating study
Trial: NCT04464239
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-142 tablets
Trial: NCT04464239
Drug: TS-142 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-142 matching placebo tablets
Trial: NCT00372957
Drug: GW823093 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White opaque capsule containing 15mg of GW823093 as free base
Trial: NCT00372957
Drug: GW823093 placebo capsule
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of GW823093 capsule or 15mg capsule
Trial: NCT00372957
Drug: GW823093 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White opaque capsule containing 15mg of GW823093 as free base
Trial: NCT00586794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x per day, 20 mg TID
Trial: NCT01889992
Drug: M-TOR Immunosuppression
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels.
Trial: NCT02229136
Drug: Miracle Mouthwash Plus Hydrocortisone
RxNorm normalized name: hydrocortisone Rectal Cream [Recort Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
Trial: NCT02229136
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone oral solution 15 mg/5 ml
Trial: NCT03031808
Drug: Muscle Relaxant (Rocuronium)
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
Trial: NCT04256525
Drug: low molecule heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4ml per day subcutaneous injection
Trial: NCT00537043
Drug: SK&F-105517 (COREG CR FDC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01069913
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation.
Trial: NCT01110057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GW856553
Trial: NCT01110057
Drug: GS856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW586553 7.5mg bid
Trial: NCT04115462
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablet of placebo
Trial: NCT04115462
Drug: Cowhage (Mucuna Pruriens)
RxNorm normalized name: cowhage (Mucuna pruriens)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Trial: NCT04115462
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
Trial: NCT04115462
Drug: Cowhage (Mucuna Pruriens)
RxNorm normalized name: cowhage (Mucuna pruriens)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Trial: NCT04622046
Drug: ALXN2060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Trial: NCT00615576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
Trial: NCT00844506
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
Trial: NCT02087527
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV normal saline every 6 hours for 48 hours
Trial: NCT01959165
Drug: MEDI7183 medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
Trial: NCT01959165
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by SC on Day 1, Week 2,4, and 8
Trial: NCT01128569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhaler
Trial: NCT00894387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02300233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
Trial: NCT04435314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo TID for 7 days.
Trial: NCT03745950
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
Trial: NCT02746302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02115321
Drug: MK-5172A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
Trial: NCT01072526
Drug: Euphrasia-based homeopathic therapy
RxNorm normalized name: Euphrasia officinalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution; 1 drop both eyes twice daily
Trial: NCT01816295
Drug: Testosterone Solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered topically to axillae.
Trial: NCT01816295
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered topically to axillae.
Trial: NCT03099122
Drug: Mycophenolate Na
RxNorm normalized name: MYCOPHENOLATE NA 180MG TAB,EC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT02448199
Drug: Meloxicam and Glucosamine
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT02448199
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT02448199
Drug: Glucosamine
RxNorm normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT03792308
Drug: SPR206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13.
Trial: NCT03792308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Trial: NCT04378868
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics are given while waiting surgery.
Trial: NCT03400423
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.
Trial: NCT02347605
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00329043
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection either monthly for 3 months or in a single 3-month dose.
Trial: NCT03179878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03261830
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
Trial: NCT00897026
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00897026
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01991860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
Trial: NCT04211363
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream for topical application.
Trial: NCT02801786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The arm will be composed of 03 women who used placebo capsules and gel.
Trial: NCT02213029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off white oral placebo tablets to match 5mg epelsiban
Trial: NCT02213029
Drug: Ortho-Cylcen (21)® tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
Trial: NCT00658268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml, single dose mixed in bone graft at operation
Trial: NCT00226005
Drug: PTK787/ZK222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Trial: NCT00967616
Drug: CS7017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
Trial: NCT03675802
Drug: dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: giving dinoprostine
Trial: NCT00967616
Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)
Trial: NCT03627052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily in the double-blind period.